N Le Stang1, V Bouvier2, O Glehen3, L Villeneuve3, F Galateau-Sallé4, B Clin5. 1. Multicenter National Mesothelioma Registry (MESONAT), Léon Bérard Cancer Center, Lyon, F-69008, France; FRANCIM Network, Toulouse, F-31000, France. Electronic address: nolwenn.lestang@lyon.unicancer.fr. 2. FRANCIM Network, Toulouse, F-31000, France; Digestive Cancer Registry, University Hospital, Caen, F-14033, France; INSERM U1086 « ANTICIPE », Caen University, F-14000, Caen, France. 3. RENAPE Referent National Center, Hospices Civils de Lyon, Lyon, F-69010, France. 4. Multicenter National Mesothelioma Registry (MESONAT), Léon Bérard Cancer Center, Lyon, F-69008, France; FRANCIM Network, Toulouse, F-31000, France; MESOPATH Referent National Center, Léon Bérard Cancer Center, Lyon, F-69008, France. 5. INSERM U1086 « ANTICIPE », Caen University, F-14000, Caen, France; Occupational Diseases Department, University Hospital, Caen, F-14033, France.
Abstract
BACKGROUND: Peritoneal malignant mesothelioma is a rare disease for which few population-based studies are available. The aim of this study was to describe the evolution of the incidence and survival of peritoneal malignant mesothelioma in France between 1989 and 2015, using data derived from the French network of cancer registries. METHODS: Age world-standardized incidence rates and overall survival were calculated using data from 16 French cancer registries. Log-linear Poisson regression analysis was used to estimate the average annual percentage change in incidence rates. Overall survival was performed using age-adjusted Cox proportional hazards model. RESULTS: In French men, the incidence has increased quietly over the reporting period from 0.07 to 0.10 with a maximum of 0.16 per 100,000 persons-years in 2001-2003. For women, the increase in incidence has been lower than for men over the period 1989-2015, ranging from 0.04 to 0.11. A better prognosis was associated with a diagnosis made after 2000 (HR = 1.76; p = 0.013), the epithelioid histological type (p = 0.003), and the fact of being a woman, which has a 5-year risk of death half that of men (HR = 0.55; p = 0.001), regardless of age, diagnosis period or histology. CONCLUSION: Our results are similar to those currently available for other countries. In France, peritoneal mesothelioma remains a rare and fatal cancer with a small increase in the incidence rate since 1989 and a median survival of 1 year; it seemed to develop equally in women and men over this period of time.
BACKGROUND: Peritoneal malignant mesothelioma is a rare disease for which few population-based studies are available. The aim of this study was to describe the evolution of the incidence and survival of peritoneal malignant mesothelioma in France between 1989 and 2015, using data derived from the French network of cancer registries. METHODS: Age world-standardized incidence rates and overall survival were calculated using data from 16 French cancer registries. Log-linear Poisson regression analysis was used to estimate the average annual percentage change in incidence rates. Overall survival was performed using age-adjusted Cox proportional hazards model. RESULTS: In French men, the incidence has increased quietly over the reporting period from 0.07 to 0.10 with a maximum of 0.16 per 100,000 persons-years in 2001-2003. For women, the increase in incidence has been lower than for men over the period 1989-2015, ranging from 0.04 to 0.11. A better prognosis was associated with a diagnosis made after 2000 (HR = 1.76; p = 0.013), the epithelioid histological type (p = 0.003), and the fact of being a woman, which has a 5-year risk of death half that of men (HR = 0.55; p = 0.001), regardless of age, diagnosis period or histology. CONCLUSION: Our results are similar to those currently available for other countries. In France, peritoneal mesothelioma remains a rare and fatal cancer with a small increase in the incidence rate since 1989 and a median survival of 1 year; it seemed to develop equally in women and men over this period of time.
Authors: Sophia F Magkouta; Apostolos G Pappas; Photene C Vaitsi; Panagiotis C Agioutantis; Ioannis S Pateras; Charalampos A Moschos; Marianthi P Iliopoulou; Chrysavgi N Kosti; Heleni V Loutrari; Vassilis G Gorgoulis; Ioannis T Kalomenidis Journal: JCI Insight Date: 2020-06-18